Eficácia e segurança do hidrato de cloral na sedação de lactentes para testes de função pulmonar

IF 1.4 Q3 PEDIATRICS
Gustavo Falbo Wandalsen , Fernanda de Cordoba Lanza , Márcia Cristina Pires Nogueira , Dirceu Solé
{"title":"Eficácia e segurança do hidrato de cloral na sedação de lactentes para testes de função pulmonar","authors":"Gustavo Falbo Wandalsen ,&nbsp;Fernanda de Cordoba Lanza ,&nbsp;Márcia Cristina Pires Nogueira ,&nbsp;Dirceu Solé","doi":"10.1016/j.rpped.2016.05.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To describe the efficacy and safety of chloral hydrate sedation in infants for pulmonary function tests.</p></div><div><h3>Methods</h3><p>All sedation attempts for pulmonary function tests in infants carried out between June 2007 and August 2014 were evaluated. Obstructive sleep apnea and heart disease were contraindications to the exams. Anthropometric data, exam indication, used dose, outcomes of sedation and clinical events were recorded and described.</p></div><div><h3>Results</h3><p>The sedation attempts in 277 infants (165 boys) with a median age of 51.5 weeks of life (14 to 182 weeks) were evaluated. The main indication for the tests was recurrent wheezing (56%) and the chloral hydrate dose ranged from 50 to 80mg/kg (orally). Eighteen (6.5%) infants had some type of clinical complication, with the most frequent being cough and/or airway secretion (1.8%); respiratory distress (1.4%) and vomiting (1.1%). A preterm infant had bradycardia for approximately 15 minutes, which was responsive to tactile stimulation. All observed adverse effects were transient and there was no need for resuscitation or use of injectable medications.</p></div><div><h3>Conclusions</h3><p>The data demonstrated that chloral hydrate at the employed doses is a safe and effective medicament for sedation during short procedures in infants, such as pulmonary function tests. Because of the possibility of severe adverse events, recommendations on doses and contraindications should be strictly followed and infants should be monitored by trained staff.</p></div>","PeriodicalId":21311,"journal":{"name":"Revista Paulista De Pediatria","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rpped.2016.05.002","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Paulista De Pediatria","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0103058216300272","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 6

Abstract

Objective

To describe the efficacy and safety of chloral hydrate sedation in infants for pulmonary function tests.

Methods

All sedation attempts for pulmonary function tests in infants carried out between June 2007 and August 2014 were evaluated. Obstructive sleep apnea and heart disease were contraindications to the exams. Anthropometric data, exam indication, used dose, outcomes of sedation and clinical events were recorded and described.

Results

The sedation attempts in 277 infants (165 boys) with a median age of 51.5 weeks of life (14 to 182 weeks) were evaluated. The main indication for the tests was recurrent wheezing (56%) and the chloral hydrate dose ranged from 50 to 80mg/kg (orally). Eighteen (6.5%) infants had some type of clinical complication, with the most frequent being cough and/or airway secretion (1.8%); respiratory distress (1.4%) and vomiting (1.1%). A preterm infant had bradycardia for approximately 15 minutes, which was responsive to tactile stimulation. All observed adverse effects were transient and there was no need for resuscitation or use of injectable medications.

Conclusions

The data demonstrated that chloral hydrate at the employed doses is a safe and effective medicament for sedation during short procedures in infants, such as pulmonary function tests. Because of the possibility of severe adverse events, recommendations on doses and contraindications should be strictly followed and infants should be monitored by trained staff.

水合氯醛在婴儿肺功能试验中的镇静作用和安全性
目的探讨水合氯醛镇静用于婴儿肺功能检查的有效性和安全性。方法对2007年6月至2014年8月间进行的所有婴儿肺功能检查镇静尝试进行评估。阻塞性睡眠呼吸暂停和心脏病是检查的禁忌症。记录和描述人体测量数据、检查指征、使用剂量、镇静结果和临床事件。结果对277例新生儿(男婴165例)的镇静尝试进行了评估,这些婴儿的中位年龄为51.5周(14 ~ 182周)。试验的主要指征是反复喘息(56%),水合氯醛剂量范围为50至80mg/kg(口服)。18例(6.5%)婴儿出现某种类型的临床并发症,最常见的是咳嗽和/或气道分泌物(1.8%);呼吸窘迫(1.4%)和呕吐(1.1%)。早产儿有大约15分钟的心动过缓,这是对触觉刺激的反应。所有观察到的不良反应都是短暂的,不需要复苏或使用注射药物。结论水合氯醛是一种安全有效的药物,用于婴儿短时间的镇静,如肺功能检查。由于可能发生严重不良事件,应严格遵守有关剂量和禁忌症的建议,并由训练有素的工作人员对婴儿进行监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Revista Paulista De Pediatria
Revista Paulista De Pediatria Medicine-Pediatrics, Perinatology and Child Health
CiteScore
2.30
自引率
0.00%
发文量
100
审稿时长
11 weeks
期刊介绍: The Revista Paulista de Pediatria publishes original contributions, case reports and review of clinical research with methodological approach in the areas of health and disease of neonates, infants, children and adolescents. The objective is to disseminate research with methodological quality on issues that comprise the health of children and adolescents. All articles are freely available online, via SciELO. Its abbreviated title is Rev. Paul. Pediatr., which should be used in bibliographies, footnotes and bibliographical references and strips.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信